Showing 4401-4410 of 5910 results for "".
- Trukera Medical Launches ScoutPro Osmolarity Systemhttps://modernod.com/news/trukera-medical-launches-new-scoutpro-osmolarity-system/2481081/Trukera Medical unveiled the first product under the new company name, the ScoutPro Osmolarity System. Designed to help advance corneal health decisions for busy eye care practices, ScoutPro is the first and only portable osmometer in the United States. The launch comes a wee
- Cellusion and Celregen Enter into License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater Chinahttps://modernod.com/news/cellusion-and-celregen-enter-into-license-agreement-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy-in-the-greater-china/2481079/Cellusion, a Japanese regenerative medicine startup, and Hangzhou Celregen Therapeutics, a member of Shanghai Fosun Pharmaceutical, announced an exclusive license agreement in the Greater China region for Celregen to develop, manufacture and commercialize CLS001. Under the agr
- ESCRS Launches New Awards Program to Foster Digital Transformationhttps://modernod.com/news/escrs-launches-new-awards-program-to-foster-digital-transformation/2481078/The European Society of Cataract & Refractive Surgeons (ESCRS) announced the launch of the 2022 ESCRS Digital Research Awards (DRA), an initiative sponsored by the society to support and encourage innovative research that leads to digital transformation in the fields of cataract, re
- American Academy of Ophthalmology Urges CMS to Address Prior Authorization, Other Burdens in Medicare Advantagehttps://modernod.com/news/american-academy-of-ophthalmology-urges-cms-to-address-prior-authorization-other-burdens-in-medicare-advantage/2481072/In a comment letter submitted to the Centers for Medicare and Medicaid Services (CMS), the American Academy of Ophthalmology (AAO), called on CMS to increase oversight and reform prior authorization, step therapy, and medical record requests in Medicare Advantage plans.
- Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and Wet AMD for 12- and 16-Week Dosinghttps://modernod.com/news/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wet-amd-for-12-and-16-week-dosing/2481071/Regeneron Pharmaceuticals announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The PHOTON trial in DME and the PUL
- First US Patient Receives Autologous Stem Cell Therapy to Treat Dry AMDhttps://modernod.com/news/first-us-patient-receives-autologous-stem-cell-therapy-to-treat-dry-amd/2481061/At the National Institutes of Health, a surgical team successfully implanted a patch of tissue made from patient cells with the goal of treating advanced dry age-related macular degeneration (AMD), also known as geographic atrophy. The patient received the therapy as part of
- Vyluma Completes Last Patient Visit for Phase 3 CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-completes-last-patient-visit-for-primary-analysis-of-pivotol-phase-iii-champ-study-evaluating-nvk002-for-the-treatment-of-myopia-progression-in-children/2481059/Vyluma announced that the last patient visit has been completed for the primary analysis of the pivotal phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. The CHAMP study has been designed, in collaboration with the FDA, to evaluate whether NVK002 eye drops are safe and eff
- Isarna Therapeutics Presents Update From Phase 2 BETTER Study in Wet AMD and DME at the EURETINA Meetinghttps://modernod.com/news/isarna-therapeutics-presents-update-from-phase-2-better-clinical-study-in-wet-amd-and-dme-at-the-euretina-meeting/2481056/Isarna Therapeutics presented an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Marion Munk, MD, PhD, FEBO, and the CMO of Isarna Therapeutics provided initial positive safety results and effic
- Bausch + Lomb Announces Strategic Partnership With Munich Surgical Imaging GmbHhttps://modernod.com/news/bausch-lomb-announces-strategic-partnership-with-munich-surgical-imaging-gmbh-1/2481053/Bausch + Lomb announced its strategic partnership with Munich Surgical Imaging GmbH (MSI)—a wholly‐owned subsidiary of Heidelberg Engineering GmbH. Based in Munich, Germany, MSI develops state‐of‐the art digital visualization and image‐guided surgical applications. The new MSI platform, dev
- Outlook Therapeutics Resubmits Biologics License Application to FDA for Wet AMD Drug Candidate ONS-5010https://modernod.com/news/outlook-therapeutics-re-submits-biologics-license-application-for-ons-5010-as-a-treatment-for-wet-amd-to-the-fda/2481052/Outlook Therapeutics announced it has resubmitted its biologics license application (BLA) to the FDA for ONS-5010, an investigational ophthalmic therapy which, if approved, will be branded as Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD